Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 15, 2022 07:00 ET | Source: Kamada Ltd.

Kamada Announces Resolution to the Labor Strike at the Company’s Manufacturing Facility in Israel; A New, Eight-Year Collective Agreement Signed

REHOVOT, Israel, July 15, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA) (KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics,...
July 06, 2022 06:00 ET | Source: Kamada Ltd.

Kamada Announces $11.4 Million International VARIZIG® Procurement Agreement

Procurement Agreement Following a New Tender Won from an International Organization Operating Principally in Latin AmericaProduct Supply Expected During the Fourth Quarter of 2022 and the First Half...
June 15, 2022 07:00 ET | Source: Kamada Ltd.

Kamada Strengthens Senior Leadership Team; Furthering Commitment as a Fully Integrated Global Leader in the Specialty Plasma-Derived Therapeutics Market

REHOVOT, Israel, and HOBOKEN, N.J., June 15, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty...
June 01, 2022 07:00 ET | Source: Kamada Ltd.

Kamada to Host a Virtual Analysts and Investors Meeting to Review its Growth Catalysts

REHOVOT, Israel, June 01, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics,...
May 17, 2022 07:05 ET | Source: Kamada Ltd.

Kamada Reports First Quarter 2022 Financial Results; Reiterates Revenue and Profitability Guidance with Significant Growth Expected in 2022

First Quarter 2022 Revenues were $28.1 Million, Up 13% Year Over Year.Kamada Reiterates Fiscal Year 2022 Revenue Guidance of $125 - $135 Million, Representing a 20% to 30% Increase over 2021 and...
May 17, 2022 07:00 ET | Source: Kamada Ltd.

Kamada Announces Expansion of Pivotal Phase 3 Clinical Trial of Inhaled AAT to Additional Six Clinical Sites Across Europe; and Positive Recommendation by DSMB to Continue the Trial Without Modification

REHOVOT, Israel, May 17, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived...
May 11, 2022 07:00 ET | Source: Kamada Ltd.

Kamada to Announce First Quarter Ended March 31, 2022 Financial Results and Host Conference Call on May 17, 2022

REHOVOT, Israel, May 11, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics,...
March 15, 2022 07:05 ET | Source: Kamada Ltd.

Kamada Issues 2022 CEO Letter to Shareholders

REHOVOT, Israel, March 15, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived...
March 15, 2022 07:00 ET | Source: Kamada Ltd.

Kamada Reports Fiscal Year and Fourth Quarter 2021 Financial Results; Provides Revenue and Profitability Guidance with Significant Growth Expected in 2022

Total Revenues for Fiscal Year 2021 were $103.6 Million and Fourth Quarter 2021 Revenues were $31.5 Million. Fiscal Year 2022 Revenues are Expected to Range Between $125 Million to $135 Million,...
March 14, 2022 08:00 ET | Source: Kamada Ltd.

Kamada Expands U.S. Leadership Team with Two Key Appointments

REHOVOT, Israel, March 14, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived...